Remdesivir reduced recovery time from coronavirus by 5 days, company says final study – National


Final data from remdesivir, an antiviral drug from Gilead Sciences Inc, showed that the treatment reduced recovery time from COVID-19 by five days compared to patients who received a placebo, one day faster than indicated in the data preliminary, the company and researchers said Thursday.In patients on oxygen when they first received the drug, remdesivir – sold under the brand name Veklury – reduced recovery time by seven days compared to placebo after 29 days, according to the study of 1,062 patients. published in the New England Journal of Medicine.

Read more:

Health Canada approves remdesivir to treat severe COVID-19

The final study looked at data at 29 days of treatment, compared to a preliminary study published in May that reported results after 15 days.

[ Sign up for our Health IQ newsletter for the latest coronavirus updates ]
Gilead’s drug was among the first to be used as a treatment for the novel coronavirus, and was one of the drugs recently used to treat US President Donald Trump.

The story continues under the ad

Health issues: Health Canada gives the green light to remdesivir

Health issues: Health Canada gives the green light to remdesivir

Remdesivir received emergency use authorization from the United States Food and Drug Administration on May 1 and has since been authorized for use in several other countries.

The results of the overall study suggest that the drug may reduce mortality, but the benefit was not statistically significant. In a separate analysis that focused only on patients who received oxygen, however, the drug appeared to reduce the risk of death by 72% on day 15 and 70% on day 29.

Read more:

Experts slam US for racking up global supply of remdesivir – only licensed COVID-19 drug

With this analysis, “we now have data suggesting that administering remdesivir to patients on oxygen can significantly reduce their risk of death compared to other subgroups,” Dr Andre Kalil, infectious disease expert at the center University of Nebraska medical and study director investigator, said in a press release.

The story continues under the ad

(Report by Julie Steenhuysen edited by Chris Reese and Sonya Hepinstall)

Show link »


Please enter your comment!
Please enter your name here